# Systemic inflammation and response to anti-inflammatory interventions in treatment-resistant depression - URL: https://alisanburak.com/en/wcp-2026-posterler/ev1125 - Language: en - Last updated: not specified - Page title: Systemic inflammation and response to anti-inflammatory interventions in treatment-resistant depression | WCP 2026 Summary > Response to anti-inflammatory interventions is primarily observed in patients with elevated inflammatory markers at baseline, suggesting the existence of biolo… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev1125) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV1125 E-PosterPsychopharmacologySystematic review # Systemic inflammation and response to anti-inflammatory interventions in treatment-resistant depression SYSTEMIC INFLAMMATION AND RESPONSE TO ANTI-INFLAMMATORY INTERVENTIONS IN TREATMENT-RESISTANT DEPRESSION Presenter: Igor P. Oliveira Country: Brazil Institution: Universidade Nove de Julho Response to anti-inflammatory interventions is primarily observed in patients with elevated inflammatory markers at baseline, suggesting the existence of biological subgroups in treatment-resistant depression. The aim of this study was to synthesize clinical evidence on the relationship between systemic inflammation and response to anti-inflammatory interventions in treatment-resistant depression (TRD). PubMed, Embase, and PsycINFO were searched through January 2025; randomized controlled trials (RCTs) and meta-analyses evaluating anti-inflammatory interventions in adults with TRD were included, while observational studies, preclinical research, and case reports were excluded. Outcome measures included antidepressant response, remission, and associations with systemic inflammatory markers, and ten studies met the predefined eligibility criteria. COX-2 inhibitors such as celecoxib produced significant symptom reductions in multiple studies, with reported effect sizes ranging from 0.4 to 0.6. Immunomodulators such as minocycline showed moderate benefits, particularly for motivational symptoms. Therapeutic response was consistently associated with elevated baseline levels of C-reactive protein (CRP) and pro-inflammatory cytokines, with less benefit observed in patients without inflammatory activation. The authors conclude that anti-inflammatory strategies are a promising adjunctive approach for patients with elevated inflammatory markers, while further studies are needed to establish standardized patient selection criteria and evaluate long-term safety. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1482) How to cite this study APA 7: Oliveira, I. P., et al. (2026, September 23-26). Systemic inflammation and response to anti-inflammatory interventions in treatment-resistant depression [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1482 Vancouver: Oliveira IP, et al. Systemic inflammation and response to anti-inflammatory interventions in treatment-resistant depression [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1482 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev1125 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim